Surging global prevalence of Crohn's disease and ulcerative colitis, expanding clinical adoption of targeted biological immunomodulators, and continuous pharmaceutical breakthroughs in oral small-molecule inhibitors are driving rapid growth across the global Inflammatory Bowel Disease (IBD) Treatment Market. IBD therapeutics—comprising anti-tumor necrosis factor (TNF) biologics,...
